|
|
News Breaks | | | | January 9, 2013 | | 16:25 EDT |  | PKI | PerkinElmer rises over 4% after Verinata pact on prenatal test
PerkinElmer (PKI) traded up today after announcing a collaboration this morning with Verinata Health to expand access to the non-invasive prenatal test for Down syndrome and other chromosomal abnormalities. Under the terms of the collaboration agreement, PerkinElmer will serve as an exclusive Verinata Health commercial partner in the joint sales and marketing of the test in the United States. The collaboration consolidates and streamlines delivery of prenatal testing options due to the combination of PerkinElmer’s extensive prenatal testing menu with Verinata’s proprietary technologies for the early, non-invasive identification of specific fetal chromosomal aneuploidies. PerkinElmer shares closed up $1.34, or 4.06%, to $34.36. | |
|
News For PKI From The Last 14 Days Check below for free stories on PKI the last two weeks. |
|
|
| May 20, 2013 | | 14:06 EDT | | PKI | Illumina says Verinata reimbursements exceeding expectations
At the UBS Healthcare Conference earlier today, Illumina (ILMN) CFO Marc Stapley said adoption for the company's Verinata prenatal test has met expectations, while reimbursement for the test has exceeded expectations, adding that its relationship with PerkinElmer (PKI) has allowed the company to obtain significant coverage decisions. In afternoon trading, shares of Illumina are up $1.48, or 2.06%, to $73.48. | | | May 16, 2013 | | 08:17 EDT |  | PKI | PerkinElmer has a conference call hosted by JPMorgan
JPMorgan Analyst Peterson will host a conference call with CEO Rob Friel and CFO Andy Wilson on May 16 at 11 am. | | | May 15, 2013 | | 06:36 EDT | | PKI | Illumina to partner for automation of sample preparation kits
 Subscribe for More Information | |
|
|
|
|
|
|
